Feed Preview

Graft vs Host Disease

Graft vs Host Disease diagram by Reddy  et al, Wikimedia
Reddy et al, Wikimedia

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Here is the latest research.


Top 20 most recent papers
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia

Cutaneous manifestations of acute and chronic graft-versus-host disease

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E SifilografiaFebruary 27, 2020
Ara ChoRobert Knobler
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation

FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and RehabilitationFebruary 27, 2020
Bellinda L King-KallimanisPaul G Kluetz
11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation

A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow TransplantationFebruary 24, 2020
Anat SternGenovefa A Papanicolaou
6
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Donor-targeted Serotherapy as a Rescue Therapy for Steroid-resistant Acute GVHD after HLA-mismatched Kidney Transplantation

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant SurgeonsFebruary 18, 2020
Julien ZuberRémi Salomon
Stem Cell Reviews and Reports

Infusion of Mesenchymal Stem Cells to Treat Graft Versus Host Disease: the Role of HLA-G and the Impact of its Polymorphisms

Stem Cell Reviews and ReportsFebruary 24, 2020
Bernardo ZoehlerMaria Da Graça Bicalho
The New England Journal of Medicine

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

The New England Journal of MedicineFebruary 27, 2020
Jonathan U PeledMarcel R M van den Brink
358
1
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical OncologyFebruary 22, 2020
Jason TayDean Fergusson
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation

MATCHED-PAIR ANALYSIS OF TRANSPLANT FROM HAPLOIDENTICAL, UNMANIPULATED BONE MARROW DONOR VERSUS HLA IDENTICAL SIBLING FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow TransplantationFebruary 19, 2020
William ArceseRome Transplant Network
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation

Comparison of outcomes of myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow TransplantationFebruary 24, 2020
Inga HofmannLeslie Lehmann
1
British Journal of Clinical Pharmacology

Population Pharmacokinetics and Bayesian Estimators for Intravenous Mycophenolate Mofetil in Haematopoietic Stem Cell Transplant Patients

British Journal of Clinical PharmacologyFebruary 20, 2020
Marc LabriffeJean-Baptiste Woillard

See more papers from this feed

Related Feeds

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Exosomes & Tumor Environment

Several studies have reported the role of exosomes as important mediators of angiogenesis, metastasis, and immune modulation. Exosomes also have the potential to be used as biomarkers for clinical predictions. Here is the latest research on exosomes and the tumor microenvironment.

Graft Rejection

Graft rejection occurs when the donor's grafted tissue is rejected by the recipient's immune system, destroying the transplanted tissue. Discover the latest research on graft rejection here.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immuno-Oncology

Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Metastatic Malignancy Treatments

Treatment of metastatic cancers depends on the type of cancer and the severity of the disease. The regime often includes medications such as chemotherapy or hormone therapy, but may also include immunotherapy, radiation therapy, surgery or a combination. Discover the latest research on metastatic cancer treatments here.

Tumor Evasion of the Immune System

Tumor evasion of the immune system includes cells that operate their own growth and develop various strategies to escape from immune surveillance. Discover the latest research on tumor evasion of the immune system here.

Tumor Vaccines

Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. Discover the latest research on tumor vaccines here.

© 2020 Meta ULC. All rights reserved
/feed-previews/graft-vs-host-disease/20952976-c76e-40c1-a801-01217ab8745e